Publications by authors named "Tianshuang Wu"

Claim this Profile
L
Long-Term Safety and Efficacy of Risankizumab to Treat Moderate-to-Severe Plaque Psoriasis: Final LIMMitless Phase 3, Open-Label Extension Trial Results.
Kim A Papp, Mark G Lebwohl, Lluís Puig, Mamitaro Ohtsuki, Stefan Beissert, Tianshuang Wu

Am J Clin Dermatol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rapid Itch Improvement and Skin Clearance with Upadacitinib Versus Placebo (Measure Up 1 and Measure Up 2) and Versus Dupilumab (Heads Up): Results from Three Phase 3 Clinical Trials in Patients with Moderate-to-Severe Atopic Dermatitis.
Eric L Simpson, Jonathan I Silverberg, Vimal H Prajapati, Kilian Eyerich, Norito Katoh, Tianshuang Wu

Dermatol Ther (Heidelb)· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of risankizumab versus methotrexate in patients with moderate-to-severe plaque psoriasis: results from IMMbrace, a randomized, double-blind, phase 3 study with an open-label extension period in Brazil.
Tania F Cestari, Cacilda da Silva Souza, Luna Azulay-Abulafia, Ricardo Romiti, André V E Carvalho, Tianshuang Wu

An Bras Dermatol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cedirogant in adults with psoriasis: a phase II, randomized, placebo-controlled clinical trial.
Stephen Tyring, Angela Moore, Akimchi Morita, H Chih-Ho Hong, In-Ho Song, Tianshuang Wu

Clin Exp Dermatol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Descriptive, Post Hoc Analysis of Efficacy and Safety of Risankizumab in Diverse Racial and Ethnic Patient Populations With Moderate-to-Severe Psoriasis.
Andrew F Alexis, Melinda Gooderham, Shawn G Kwatra, Ahmad Amin, Susan Taylor, Tianshuang Wu

Dermatol Ther (Heidelb)· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of long-term risankizumab treatment for moderate-to-severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks (LIMMitless trial).
Bruce Strober, Hervé Bachelez, Jeffrey Crowley, Boni E Elewski, Melinda Gooderham, Tianshuang Wu

J Eur Acad Dermatol Venereol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up.
Kim A Papp, Andrew Blauvelt, Lluís Puig, Mamitaro Ohtsuki, Stefan Beissert, Tianshuang Wu

J Am Acad Dermatol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse).
Linda F Stein Gold, Jerry Bagel, Stephen K Tyring, H Chih-Ho Hong, Lev Pavlovsky, Tianshuang Wu

Br J Dermatol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: Results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up).
Andrew Blauvelt, Barry Ladizinski, Vimal H Prajapati, Vivian Laquer, Alison Fischer, Tianshuang Wu

J Am Acad Dermatol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Switching to risankizumab from ustekinumab or adalimumab in plaque psoriasis patients improves PASI and DLQI outcomes for sub-optimal responders.
Bruce Strober, April Armstrong, Simone Rubant, Manish Patel, Tianshuang Wu

J Dermatolog Treat· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis in the Russian Federation.
Liudmila Odnopozova, Anton Edin, Alexey Sukharev, Tianshuang Wu, Kerstin Aydin

Dermatol Ther (Heidelb)· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Performance and Predictors of Minimal Disease Activity Response in Patients With Peripheral Spondyloarthritis Treated With Adalimumab.
Laura C Coates, Sonya Abraham, William Tillett, Philip J Mease, Sofia Ramiro, Tianshuang Wu

Arthritis Care Res (Hoboken)· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study.
Jeffrey J Crowley, Richard G Langley, Kenneth B Gordon, Andreas Pinter, Laura K Ferris, Tianshuang Wu

Dermatol Ther (Heidelb)· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial.
Andrew Blauvelt, Henrique D Teixeira, Eric L Simpson, Antonio Costanzo, Marjolein De Bruin-Weller, Tianshuang Wu

JAMA Dermatol· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Power analysis in a SMART design: sample size estimation for determining the best embedded dynamic treatment regime.
William J Artman, Inbal Nahum-Shani, Tianshuang Wu, James R Mckay, Ashkan Ertefaie

Biostatistics· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sample size considerations for comparing dynamic treatment regimens in a sequential multiple-assignment randomized trial with a continuous longitudinal outcome.
Nicholas J Seewald, Kelley M Kidwell, Inbal Nahum-Shani, Tianshuang Wu, James R McKay

Stat Methods Med Res· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial.
Andrew Blauvelt, Craig L Leonardi, Melinda Gooderham, Kim A Papp, Sandra Philipp, Jashin J Wu, Tianshuang Wu

JAMA Dermatol· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identifying a set that contains the best dynamic treatment regimes.
Ashkan Ertefaie, Tianshuang Wu, Kevin G Lynch, Inbal Nahum-Shani

Biostatistics· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis